Staphylococcal Toxic Shock Syndrome 2000–2006: Epidemiology, Clinical Features, and Molecular Characteristics by DeVries, Aaron S. et al.
Staphylococcal Toxic Shock Syndrome 2000–2006:
Epidemiology, Clinical Features, and Molecular
Characteristics
Aaron S. DeVries
1*, Lindsey Lesher
1, Patrick M. Schlievert
2, Tyson Rogers
3¤a, Lourdes G. Villaume
1,3¤b,
Richard Danila
1, Ruth Lynfield
1
1Minnesota Department of Health, Emerging Infections Program, St. Paul, Minnesota, United States of America, 2Department of Microbiology, University of Minnesota,
Minneapolis, Minnesota, United States of America, 3Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
Abstract
Introduction: Circulating strains of Staphylococcus aureus (SA) have changed in the last 30 years including the emergence of
community-associated methicillin-resistant SA (MRSA). A report suggested staphylococcal toxic shock syndrome (TSS) was
increasing over 2000–2003. The last population-based assessment of TSS was 1986.
Methods: Population-based active surveillance for TSS meeting the CDC definition using ICD-9 codes was conducted in the
Minneapolis-St. Paul area (population 2,642,056) from 2000–2006. Medical records of potential cases were reviewed for case
criteria, antimicrobial susceptibility, risk factors, and outcome. Superantigen PCR testing and PFGE were performed on
available isolates from probable and confirmed cases.
Results: Of 7,491 hospitalizations that received one of the ICD-9 study codes, 61 TSS cases (33 menstrual, 28 non-menstrual)
were identified. The average annual incidence per 100,000 of all, menstrual, and non-menstrual TSS was 0.52 (95% CI, 0.32–
0.77), 0.69 (0.39–1.16), and 0.32 (0.12–0.67), respectively. Women 13–24 years had the highest incidence at 1.41 (0.63–2.61).
No increase in incidence was observed from 2000–2006. MRSA was isolated in 1 menstrual and 3 non-menstrual cases (7%
of TSS cases); 1 isolate was USA400. The superantigen gene tst-1 was identified in 20 (80%) of isolates and was more
common in menstrual compared to non-menstrual isolates (89% vs. 50%, p=0.07). Superantigen genes sea, seb and sec
were found more frequently among non-menstrual compared to menstrual isolates [100% vs 25% (p=0.4), 60% vs 0%
(p,0.01), and 25% vs 13% (p=0.5), respectively].
Discussion: TSS incidence remained stable across our surveillance period of 2000–2006 and compared to past population-
based estimates in the 1980s. MRSA accounted for a small percentage of TSS cases. tst-1 continues to be the superantigen
associated with the majority of menstrual cases. The CDC case definition identifies the most severe cases and has been
consistently used but likely results in a substantial underestimation of the total TSS disease burden.
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Introduction
A syndrome of fever, myalgias, sore throat, edema, scarlitini-
form rash, and desquamation associated with Staphylococcus aureus
(SA) infection was first described in 1927, and in 1978 Todd et al.
coined the term staphylococcal toxic shock syndrome (TSS) [1–2].
By 1980, young menstruating women using high absorbency
tampons were identified as a high risk group, with cases also
observed in men and non-menstruating women [3–4]. As the
pathogenesis was better understood, it became clear that SA toxins
called superantigens in conjunction with host susceptibility from
the absence of anti-superantigen antibodies were risk factors for
the development of TSS [5–6].
The estimated incidence of TSS in 1980 among young
menstruating women was 13.7 per 100,000 persons [7]. Following
multiple public health interventions including removal of highly
absorbent tampons and messages regarding proper use of
tampons, the number of cases declined sharply. By 1986 the rates
of menstrual and non-menstrual TSS cases were 1 and 0.3 per
100,000, respectively [8–9]. In 1986, the overall case fatality rate
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group (median age, 25 years) [9]. In the early 1980s long-term
morbidity was observed in up to 90% of TSS cases, with 20%
experiencing recurrent episodes, 50% having long-term memory
loss and abnormal EEG findings, and 23% having recurrent
syncope or cardiomyopathy [10–11]. Since 1986, there has not
been population-based active surveillance to assess the incidence
or disease burden of TSS.
Many strains of SA are known to carry genes for superantigens
including toxic shock syndrome toxin–1 (tst-1), the causative
superantigen in most TSS cases [12–14]. Prevalent strains of SA
are in constant flux. Over the past 15 years, community-associated
methicillin-resistant SA (CAMRSA) strains, most notably USA300
and USA400, have emerged as predominant causes of skin and
soft tissue infection in many geographic regions of the United
States [15–16]. Skin and soft tissue infections are a common
primary site of non-menstrual TSS [10,17]. Historically, children
and adolescents had the highest prevalence of CAMRSA
colonization and the highest incidence of CAMRSA infection,
although more recently CAMRSA has been increasing in other
age and risk groups such as hospitalized patients [18–20]. This is
relevant because children have lower frequencies of protective
anti-superantigen antibodies and are at greater risk to TSS if
exposed to superantigen-producing SA strains [21]. The repertoire
of superantigen genes produced by CAMRSA strains that are
known to cause TSS is limited. The superantigen genes for
staphylococcal enterotoxins A (sea), B (seb)o rC( sec) have been
described in USA400 [22]. seb has been associated with non-
menstrual TSS cases [12,23–25]. However, neither USA300 nor
USA400 have been described to carry tst-1 [13,25–26].
The current passive surveillance system for TSS is limited given
the complexity of the clinical diagnosis and lack of a single
diagnostic test. It is unclear whether the continually evolving
epidemiology of circulating SA strains is leading to a change in the
incidence of TSS cases. A report of a rapid increase in the number
of SA isolates from patients with TSS submitted for superantigen
testing during 2000–2003 to a Minneapolis-St. Paul metropolitan
area reference laboratory suggested that rates of disease may be on
the rise [27]. Given the possibility of an increase in the incidence
of TSS, particularly among young persons in association with
changes in SA epidemiology, we began active, population-based
surveillance to identify the current incidence of TSS in the
Minneapolis-St. Paul metropolitan area.
Methods
Cases of staphylococcal TSS are reportable to the Minnesota
Department of Health (MDH) as required by the Minnesota
Communicable Disease Rule. This study was reviewed and
approved by the Institutional Review Board as exempt research
without requirement for informed consent as this was review of
existing data. The catchment area included the 7 counties of the
Minneapolis-St. Paul (MSP) metropolitan area (Anoka, Carver,
Dakota, Hennepin, Ramsey, Scott, and Washington), with a
combined population of 2,642,056 (2000 U.S. Census). This area
encompasses 50% of the total Minnesota population and 24 acute
care hospitals from urban, suburban, and rural areas. There was
no change in the catchment area across both surveillance periods
(2000–2003 and 2004–2006).
Surveillance Period 2000–2003
ICD-9 codes were used to identify potential cases of TSS. A list
of all inpatient hospitalizations discharged between January 1,
2000 and December 31, 2003 that received at least one of the
study codes was requested from all 24 hospitals in the MSP
metropolitan area. All hospitals provided a list. Every hospitaliza-
tion that received the specific ICD-9 code for TSS (040.82 or
040.89) was reviewed (Table 1). For hospitalizations that received
at least one of the other ICD-9 codes (038.11, 038.19, 038.9,
785.50, 785.59 or 785.52), that were non-specific for TSS, a 20%
random sample from within each hospital was reviewed. The
medical records of all selected hospitalizations were reviewed for
the Centers for Disease Control and Prevention (CDC) TSS case
definition criteria (Table 2) [28] and other pertinent epidemiologic
and clinical information. From 2000–2003 potential cases were
also sought from Minnesota death certificates receiving the ICD-
10 code for toxic shock syndrome (A48.3) and from cases reported
to the Minnesota Unexplained Critical Illness and Death of
Possible Infectious Etiology project (UNEX) [29]. Methods for
surveillance from 2000–2003 were previously published [30].
Five experienced record abstractors received initial and ongoing
training in data abstraction using a Minnesota Department of
Health (MDH)-developed eight-page TSS case report form. TSS
cases were classified as menstrual if (i) the onset of symptoms was
during documented dates of menstruation or (ii), in the absence of
documented dates of menstruation, a woman was between the
ages of 13 and 54 years and a vaginal culture was positive for SA.
All other TSS cases were classified as non-menstural.
Surveillance Period 2004–2006
Based on preliminary analysis of 2000–2003, the TSS-specific
codeidentifiedcaseswith highersensitivityand specificitycompared
to othercodes and therefore onlythe TSS-specific code was used for
surveillance period of 2004–2006 [30]. A list of all inpatient
hospitalizationsdischarged between January 1, 2004 and December
31, 2006 that received the TSS-specific code was requested from all
24 hospitals in the MSP metropolitan area; all hospitals complied.
All hospitalizations were reviewed using the same methodology as
used during the surveillance period 2000–2003.
Population Denominator Calculations
Population estimates were taken from the 2000 US Census and
the inter-Census estimate for 2005. Assuming a linear rate of
Table 1. ICD-9 Study Codes Utilized for TSS Case
Ascertainment.
ICD-9 Code Associated Diagnosis
Specific toxic shock syndrome code
040.89 or 040.82* Toxic shock syndrome
Non-specific toxic shock syndrome codes
038.11 Staphylococcus aureus
septicemia
038.19{ Other staphylococcal
septicemia
038.9 Unspecified septicemia
785.50 Shock without mention
of trauma
785.59 or 785.52* Sepsis
*The ICD-9 code number assigned to ‘‘toxic shock syndrome’’ changed from
040.89 to 040.82 on October 1, 2002, and the code number assigned to ‘‘sepsis’’
changed from 785.59 to 785.52 on October 1, 2003. While the numeric codes
changed, their associated diagnoses remained unchanged and are considered
mutually exclusive.
{Code eliminated after interim analysis.
doi:10.1371/journal.pone.0022997.t001
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used for denominator calculations over the years 2000–2006. An
average population was used to calculate incidence over the 4-year
period from 2000–2003. For the estimated incidence of all TSS
and non-menstrual TSS cases, the total population was used as the
denominator. For menstrual cases, the denominator was females
aged 13–55 years, as this was the approximate age distribution
among our menstrual cases.
Statistical Analysis
Cases of TSS with a home zip code outside the MSP area were
included in the descriptive analysis of cases but were excluded
from incidence estimations, as referral patterns strongly favor cases
with home zip codes in the MSP area to be hospitalized in the
MSP area (based on culture-confirmed invasive bacterial infec-
tions, Active Bacterial Core surveillance [31] in MN. For
descriptive analysis, Student t-tests and Fisher’s Exact Chi-square
tests were used for continuous and categorical variables,
respectively.
The average annual incidence was estimated for 2000–2003 as
this was the period of most complete case ascertainment. In order
to accommodate separate sampling frequencies, the TSS incidence
rates for 2000–2003 were separately estimated among (i) the
hospitalizations assigned a TSS-specific code and (ii) the
hospitalizations assigned TSS-non-specific codes. These two
incidence rates were summed, and the overall incidence rate was
estimated by WinBugs version 1.4 software with Bayesian
statistical methods and Poisson regression. Bayesian methods were
chosen to estimate incidence rates as they can generate confidence
intervals while allowing for the different rates of sampling of TSS-
specific code and the TSS-non-specific codes. Bayesian statistics
also permitted the evaluation of differences in incidence rates
between age groups and across time. Frequentist Poisson
regressions were performed using SAS 9.2 to corroborate Bayesian
analysis and to calculate P-values for test of trend.
To assess a change in incidence over the years 2000–2006 only
those cases identified using the TSS specific code were used.
Frequentist Poisson regression was used to calculate P-values for
test of trend across time.
Characterization of isolates
All available SA isolates from confirmed or probable cases were
collected. Isolates were tested by PCR for presence of superantigen
genes tst-1, sea, seb, and sec [32]. Molecular typing of a limited
number of isolates was performed by pulsed field gel electropho-
resis (PFGE) of genomic DNA after restriction endonuclease
digestion with Sma1. PFGE patterns were compared using
Bionumerics Software34 and the Dice coefficient. USA clonal
groups were determined by PFGE per SA PFGE genotype
nomenclature [33]. Antimicrobial susceptibility testing was
performed by clinical laboratories.
Results
Case Identification
From January 1, 2000 to December 31, 2003, we identified
7,414 hospitalizations with at least one study code and 43 probable
or confirmed TSS cases, all from ICD-9 code surveillance
(Figure 1). Cases were identified at 14 of the 24 hospitals, with
89% of cases at five hospitals. From 2000–2003, no additional
cases were identified from 9 deaths coded with the ICD-10 code
for TSS and from the 153 reported UNEX cases. Among the
43 cases from 2000–2003, the TSS-specific code was more likely
to be used on menstrual cases [22/23, (96%)] compared to
Table 2. Surveillance Case Definition of TSS [28].
Clinical Criteria
1. Fever: temperature $38.9uC (102.0uF).
2. Rash: diffuse macular erythroderma.
3. Desquamation: 1–2 weeks after onset of illness, particularly on the palms and soles.
4. Hypotension: systolic blood pressure (BP) #90 mmHg for adults or less than fifth percentile by age for children aged ,16 years; orthostatic drop in diastolic blood
pressure $15 mmHg from lying to sitting, orthostatic syncope, or orthostatic dizziness.
5. Multisystem involvement (three or more of the following):
N Gastrointestinal: vomiting or diarrhea at onset of illness.
N Muscular: severe myalgia or creatine phosphokinase (CPK) level at least twice the upper limit of normal (ULN).
N Mucous membrane: vaginal, oropharyngeal, or conjunctival hyperemia.
N Renal: blood urea nitrogen (BUN) or creatinine (Cr) at least twice ULN for laboratory or urinary sediment with pyuria ($5 white blood cells [WBC] per high-power
field) in the absence of urinary tract infection.
N Hepatic: total bilirubin (T.Bili), alanine aminotransferase enzyme (ALT), or asparate aminotransferase enzyme (AST) levels at least twice ULN for laboratory.
N Hematologic: platelets #1006109/L.
N Central nervous system: disorientation or alterations in consciousness without focal neurologic signs when fever and hypotension are absent.
Laboratory criteria
6. Negative results on the following tests, if obtained:
N Blood, throat, or cerebrospinal fluid cultures (blood culture may be positive for Staphylococcus aureus).
N Rise in titer to Rocky Mountain spotted fever, leptospirosis, or measles.
Case classification
Probable case: meets the laboratory criteria and in which four of the five clinical findings described above are present.
Confirmed case: meets the laboratory criteria and in which all five of the clinical findings described above are present, including desquamation, unless the patient dies
before desquamation occurs.
doi:10.1371/journal.pone.0022997.t002
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2004 to December 31, 2006, an additional 77 hospitalizations
receiving the TSS-specific code were identified (Figure 1) of which
18 were probable or confirmed TSS cases. The total number of
TSS cases identified over years 2000–2006 was 61.
Clinical Characteristics
Among the 61 TSS cases, the median age was 21.4 years (range,
1.4–81.0). The median age was 34.8 years (range, 4.5–81) for the
13 males and 18.5 years (range, 1.4–76.5) for the 48 females (male
vs. female cases, p=0.05). There were 33 menstrual and 28 non-
menstrual TSS cases, with menstrual cases trending toward
younger age and fewer preexisting conditions (Table 3). There
were minimal differences in clinical presentation between
menstrual and non-menstrual cases.
Of the 28 non-menstrual cases, 13 (46%) had a skin or soft tissue
infection, of which 4 (31%) were post-surgical. Additionally, 10
(36%) had no primary source identified after a median of 4 (range
1, 6) sites cultured, 1 had multiple positive culture sites, 3 had
primary bacteremia, 1 had a pulmonary primary site, and 1 a
urinary tract site.
All cases were treated with antimicrobial agents, with 58 (95%)
receiving a beta-lactam, 41 (67%) clindamycin, and 30 (49%)
vancomycin. There was no significant difference in the use of
beta-lactams, clindamycin, or vancomycin between menstrual and
non-menstrual cases. Nine percent of cases were treated with
activated protein C (APC), and 19% were treated with intravenous
immunoglobulin (IVIG). Length of hospitalization was shorter in
menstrual cases compared to non-menstrual cases (median, 5 vs.
11 days, p,0.001). Cases treated with clindamycin were younger
versus those not treated with clindamycin (median 18 vs. 40 years
p=0.02) but there was no difference in the length of hospitaliza-
tion (6.5 vs. 6.0 days p=0.67) There were no significant
differences in age, sex, number with multiple organ system
involvement, or length of hospitalization between TSS cases
treated with IVIG versus no IVIG, APC versus no APC, a beta-
lactam versus a different antimicrobial agent, and vancomycin
versus a different antimicrobial agent. One death (2%) occurred in
an 80-year old male.
Menstrual cases from January 1, 2000 to June 30, 2003 (n=19)
were compared to July 1, 2003 to December 31, 2006 (n=14).
There was no significant difference in the frequency of underlying
health conditions, age, length of hospitalization, number of
positive cultures for SA or MRSA, or treatment with IVIG,
APC, beta-lactam antimicrobials, or clindamycin between these
two time periods. Vancomycin was prescribed more frequently in
July 1, 2003 to December 31, 2006 compared to January 1, 2000
to June 30, 2003 (64% vs. 21% p=0.03).
Figure 1. Flow diagram of TSS case ascertainment. From 2000–2003 TSS cases were identified from multiple data sources including ICD-9
hospital discharge codes, cases reported to the Minnesota Unexplained Critical Illness and Death of Possible Infectious Etiology project (UNEX), and
death certificate data using ICD-10 code A48.3. From 2004–2006 TSS cases were identified from only the TSS-specific ICD-9 hospital discharge code.
doi:10.1371/journal.pone.0022997.g001
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Forty-four (72%) of the 61 TSS cases had at least one positive
culture for SA; 39 had susceptibility testing results available
(Table 4). Four cases (7%) had SA isolates that were MRSA (1
menstrual, 3 non-menstrual). Two MRSA isolates, both from non-
menstrual cases, had antimicrobial susceptibility patterns sugges-
tive of CAMRSA (susceptible to quinolones, clindamycin,
tetracycline, trimethoprim-sulfamethoxazole, and gentamicin,
but resistant to oxacillin in one isolate, and resistant to oxacillin
plus erythromycin in the other isolate). One MRSA isolate from a
skin/soft tissue infection (non-menstrual) was USA400 (a known
CAMRSA clonal group) by PFGE.
Four MSSA isolates from 3 cases also had PFGE performed: a
menstrual case with USA200, a non-menstrual case with USA 200
and a menstrual case with two different SA strains from the same
vaginal culture (USA700 and USA200). There were no significant
differences in susceptibility patterns between isolates associated
with menstrual and non-menstrual cases.
Superantigen testing was performed on 26 of 44 (59%) isolates
(Table 4). At least one superantigen gene was identified in each
isolate. Tst-1 was the most frequent superantigen gene found and
was more common among menstrual vs non-menstrual cases
though not statistically significant (89% vs 50% p=0.07). Both sea
and sec were found in non-menstrual cases. Isolates with sea also
had tst-1. The three isolates with sec including two menstrual cases
did not have other superantigens. Seb was found exclusively in non-
menstrual cases (60% vs 0% p,0.01).
Incidence
Average annual incidence was estimated based on 2000–2003
surveillance. Seven TSS cases from 2000–2003 (all with the
specific TSS code) were excluded because they had home zip
codes outside of the study area, leaving 31 cases with the TSS-
specific ICD-9 code. Five cases were identified using the non-
specific TSS codes obtained from the 20% sample of hospitaliza-
tions adding 25 additional cases for a total of 56 estimated cases
from 2000 through 2003. Average annual incidence per 100,000
persons of all TSS cases was 0.52 cases (95% CI, 0.32–0.77), of
menstrual cases was 0.69 (95% CI, 0.39–1.16), and of non-
menstrual cases was 0.32 (95% CI, 0.12–0.67) (Table 5). Women
aged 13–24 years had the highest incidence with an annual rate of
menstrual TSS of 1.41 cases per 100,000 (95% CI, 0.63–2.61).
For purposes of determining if a change in annual incidence was
occurring over the years 2000–2006, the annual incidence was
estimated from cases that were coded with the TSS specific code as
this was conducted consistently over this time frame. Over the
years 2000–2006, the annual incidence rate of all TSS, menstrual
TSS, and non-menstrual TSS did not change significantly (test of
trend p=0.63, p=0.71, and p=0.77 respectively). When
stratifying menstrual and non-menstrual TSS by dichotomous
age groups of less than or equal to 24 years and greater than 24
years, there was no significant change in the incidence among the
younger menstrual TSS group (test of trend p=0.22) and younger
non-menstrual group (test of trend p=0.69) over the years 2000–
2006 (Figure 2). Similarly the older non-menstrual group did not
have a significant change in the annual incidence (test of trend
p=0.40), but older menstrual TSS group had a significant
decrease in the annual incidence (test of trend p=0.02).
Discussion
The incidence of TSS in Minnesota has declined substantially
since the first population based estimates in 1980. The greatest
Table 3. Description of Toxic Shock Syndrome Cases.
All Cases Menstrual Non-menstrual
Characteristics
n=61 (Range
or % Total)
n=33 (Range
or % Total)
n=28 (Range
or % Total) p value*
Median age (yr) 21.4 (1.4–81.0) 17.9 (12.4–52.6) 26.3 (1.4–81.0) 0.12
Female sex 48 (79%) 33 (100%) 15 (54%) ,0.001
MSP area home zip code 50 (82%) 28 (85%) 22 (79%) 0.74
Median days from first symptom to hospitalization 2 (0–7) 2 (0–7) 2 (0–7) 0.65
One or more co-morbidities{ 19 (31%) 7 (21%) 12 (43%) 0.10
All six criteria 12 (20%) 9 (27%) 3 (11%) 0.12
Temperature $38.9uC (102.0uF) 59 (97%) 32 (97%) 27 (96%) 1.00
Hypotension{ 57 (93%) 32 (97%) 25 (89%) 0.33
Rash consistent with erythroderma 60 (98%) 32 (97%) 28 (100%) 1.00
Desquamation 20 (33%) 12 (36%) 8 (29%) 0.59
Multisystem involvement1 60 (98%) 33 (100%) 27 (96%) 0.46
Any culture positive for SA 44 (72%) 28 (85%) 16 (57%) 0.02
Median days of hospitalization 6 (2–50) 5 (2–25) 11 (2–50) ,0.001
Deaths 1 (2%) 0 (0%) 1 (4%) 0.46
Abbreviations: yr, years; MSP, seven-county Minneapolis-St. Paul metropolitan area; SA, Staphylococcus aureus; MRSA Methicillin-Resistant SA; MDH, Minnesota
Department of Health.
*Comparison of menstrual and non-mentstrual TSS cases. Student t-tests were used for continuous variables and Fisher’s Exact Chi-Square tests were used for
categorical variables.
{Co-morbidities defined as in the Active Bacterial Core surveillance project [31].
{Hypotension defined as orthostatic hypotension or syncope, or systolic BP#90 mmHg if age $16 yr, #5
th percentile for age if ,16 yr.
1Multisystem involvement as defined as abnormality in three or more organ systems including gastrointestinal, muscular, mucous membranes, central nervous system,
hematologic, hepatic, or renal. See Figure 1.
doi:10.1371/journal.pone.0022997.t003
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women aged 15–24 occurred in 1980–1981. By 1986 the incidence
among young women had decreased to approximately 1.5–2.5 per
100,000 [7–8,34]. The most recent approximation of TSS case
numbers prior to this study, based on national passive case reporting
through 1996 and estimates from national insurance databases from
1999–2004, found little change inthe absolutenumberofcasessince
1986[9,35]. During 2000–2003,the time framewithmorecomplete
case ascertainment, we identified similar annual incidence rates
compared to those described in 1986 in the MSP area using active-
population based surveillance.
Despite this relative stability in TSS incidence over the last 20
years, the prevalent SA strains circulating in the community have
shifted. MRSA strains have increased in prevalence during the last
decade and MRSA have been reported as the cause of TSS
[23,36]. USA200, typically classified as a health-care associated
MRSA strain, has been identified to contain genes for tst-1 and sea
[14]. In contrast, CAMRSA strains often carry different
superantigen genes with USA400 known to contain sea, seb, sec
and/or staphylococcal enterotoxin Q (seq) and USA300 strains
known to contain staphylococcal enterotoxin K (sek) and seq but
not the most frequent superantigens associated with TSS: sea, seb,
sec and tst-1 [13,22,25–26]. One of our TSS cases had a USA400
MRSA strain.
Over the past 10 years, USA300 MRSA strains have
substantially increased in prevalence in Minnesota, replacing
USA400 as the most common strain of CAMRSA. As a
percentage of MN CAMRSA isolates obtained from sentinel site
surveillance, USA300 strains increased from 6% in 2000 to 68% in
2005. In contrast, USA400 strains decreased from 63% in 2000 to
11% in 2005 of MN CAMRSA isolates [37]. Among the 44 TSS
cases with a positive culture for SA, we identified 4 (13%) MRSA
isolates, of which one had a pulsotype commonly associated with
CAMRSA. The increasing prevalence of USA300 among
circulating strains, and the lack of TSS cases found due to
USA300 suggests that although USA300 is associated with an
increased occurrence of some staphylococcal syndromes including
skin and soft tissue infections, osteomyelitis and pneumonia, it does
not appear to be associated with TSS.
TSS remains an important cause of morbidity among young
people, with the greatest impact on young women. During our
Table 5. Average Annual Toxic Shock Syndrome Incidence by
Age and Gender Groups During the Period of Most Complete
Case Ascertainment, 2000–2003.
Annual Incidence*
Risk Group
per 100,000 Persons
at Risk (95% CI)
All TSS 0.52 (0.32–0.77)
All Males 0.23 (0.10–0.44)
All Females 0.79 (0.48–1.22)
All Menstrual TSS (age 13–54 yr) 0.69 (0.39–1.16)
Menstrual age 13–24 yr 1.41 (0.63–2.61)
Menstrual age 25–54 yr 0.43 (0.19–0.82)
All Non-menstrual TSS 0.32 (0.12–0.67)
Non-menstrual females #24 yr 0.36 (0.12–0.87)
Non-menstrual females .24 yr 0.36 (0.14–0.82)
Abbreviations: CI, Bayesian confidence interval, TSS, toxic shock syndrome; yr,
year.
*Annual incidence averaged over all study years, 2000–2003 and estimated by
Bayesian statistical methods and Poisson regression.
doi:10.1371/journal.pone.0022997.t005
Table 4. Comparison of Susceptibility Patterns and Superantigens among Isolates Associated with Menstrual and Non-menstrual
Toxic Shock Syndrome Cases.
All Cases Menstrual Non-menstrual p value*
Antimicrobial (n=44) 39/44 (88%) 25/28 (89%) 14/16 (88%) 1.00
penicillin (n=35) 0/35 (0%) 0/24 (0%) 0/11 (0%) 1.00
erythromycin (n=35) 23/35 (66%) 16/24 (67%) 7/11 (64%) 1.00
clindamycin (n=36)I 31/36 (83%) 21/24 (88%) 10/12 (83%) 1.00
oxacillin (n=38) 34/38 (89%) 24/25 (96%) 10/13 (77%) 0.11
quinolones (n=34){ 32/34 (94%) 22/23 (96%) 10/11 (91%) 1.00
TMP/SMX (n=33) 32/33 (97%) 22/23 (96%) 10/10 (100%) 1.00
gentamicin (n=19) 19/19 (100%) 16/16 (100%) 3/3 (100%) 1.00
vancomycin (n=34) 34/34 (100%) 24/24 (100%) 10/10 (100%) 1.00
Superantigen (n=44) 26/44 (59%) 19/28 (68%) 7/16 (44%) 0.20
tst-1 present (n=25) 20/25 (80%) 17/19 (89%) 3/6 (50%) 0.07
sea present (n=5) { 2/5 (40%) 1/4 (25%) 1/1 (100%) 0.40
seb present (n=20) 3/20 (15%) 0/15 (0%) 3/5 (60%) ,0.01
sec present (n=19) 3/19 (16%) 2/15 (13%) 1/4 (25%) 0.53
Abbreviations:TMP/SMX, trimethoprim-sulfamethoxazole; tst-1, toxic shock syndrome toxin 1; sea, staphylococcal enterotoxin; seb, staphylococcal enterotoxin B; sec,
staphylococcal enterotoxin C.
*Comparison of menstrual and non-mentstrual TSS cases. Fisher’s Exact Chi-Square test comparing menstrual and non-menstrual isolates.
IIncludes inducible clindamycin resistance as evidenced by D-test.
{Testing was performed on gatifloxacin, ciprofloxicin, or levofloxin based on clinical laboratory. If more than one quinolone was tested, isolate was classified as
susceptible if the all quinolones tested were susceptible.
{Both cases that where sea positive were also tst-1 positive.
doi:10.1371/journal.pone.0022997.t004
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for menstrual cases was 18 years. Cases stayed a median of 6
hospital days including intensive care unit time. While most
recover, we identified one death due to TSS. Despite public health
efforts, such as removal of high-absorbency tampon products and
public safety announcements, menstrual TSS continues to occur at
rates similar to other infections of public health importance such as
N. meningitidis (annual incidence 0.28/100,000) [38] and invasive
group A Streptococcus (annual incidence 3.6/100,000) [39].
Unfortunately, no single diagnostic test is available to clearly
identify persons with TSS. Using the CDC case definition we
found an incidence similar to past population-based estimates of
incidence. The case definition was developed in 1980 to identify
TSS risk factors and has only been slightly modified since then
with the most recent update occurring in 2011 [40]. As the
pathophysiology has been further described, a wide range in the
severity of TSS has been recognized. Individuals who seek medical
care promptly, receive appropriate early interventions, or have
partial immunity are more likely to experience a mild form of the
illness. Advances in supportive care such as early goal directed
fluid resuscitation likely prevent the development of the most
severe manifestations of the illness. Because of these factors, a large
portion of the TSS disease burden is very likely not being
identified by strictly applying the CDC TSS case definition.
Therefore, our estimates represent the incidence of the most severe
form of TSS. In the absence of a definitive diagnostic test, it is
difficult to quantify the burden of disease of less severe
presentations of TSS. For this reason, clinicians should not rely
on the epidemiologic case definition to determine when to institute
appropriate treatment for TSS as this may lead to unnecessary
morbidity.
Interestingly, there was a decrease in the rates of menstrual TSS
among women older than 24 years when comparing rates of
disease over the years 2000–2006. Possible factors leading to a
decreasing incidence include decreasing tampon use, increasing
levels of protective antibody in this population, or decreasing use
of intravaginal contraceptive devices. An additional protective
factor may be the increasing frequency of menstrual suppression
techniques within this group, as the safety and acceptability of this
practice among patients and practitioners has increased in the last
decade [41–42]. The prevalence of menstrual suppression among
women of any age group is unknown.
We conducted this study within a single geographic area. While
there is racial and ethnic diversity in the MSP area, it may not be
representative of the racial and ethnic makeup of other geographic
areas and there may be unknown factors unique to this region.
Additionally, a select group of ICD-9 codes were used to capture
cases. If additional, lower yield codes had been included, we may
have identified additional TSS cases. Therefore, our calculated
incidence likely represents a low estimate of the actual incidence.
In conclusion, we observed a stable incidence of both menstrual
and non-menstrual TSS in the years 2000–2003 compared to the
late 1980s, with the highest incidence among women aged 13–24
years. There was also no significant increase in annual TSS
incidence over the years 2000–2006. While one TSS case due to
CAMRSA (USA400) was identified, the increased prevalence of
CAMRSA in Minnesota did not appear to affect the incidence of
menstrual or non-menstrual TSS. It would be useful to conduct
surveillance for TSS cases in other populations and geographic
areas that may have different prevalent staphylococcal strains and
host susceptibilities to TSS, as well as assess the toxins produced by
implicated strains in order to monitor changes in the epidemiology
of TSS.
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Figure 2. Annual incidence of menstrual and non-menstrual
TSS across years 2000–2006. Annual incidence of TSS across years
2000–2006 of menstrual (A) and non-menstrual (B) TSS stratified by age
#24 and .24 years using only cases receiving the TSS specific ICD-9
code. Error bars represent 95% confidence limits. Frequentist Poisson
regressions were used to calculate P-values for test of trend. Over years
2000–2006 among menstrual TSS aged #24 years test of trend was not
significant (p=0.22) as was non-menstrual age #24 years (p=0.69) and
.24 years (p=0.40) There was a significant decreasing annual
incidence over 2000–2006 in menstrual TSS aged .24 years (test of
trend p=0.02).
doi:10.1371/journal.pone.0022997.g002
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